FDA Issues Qualified Health Claim Related to Yogurt, Type 2 Diabetes
By Denny Jacob
The U.S. Food and Drug Administration doesn't intend to object to certain health claims surrounding yogurt and type 2 diabetes.
The FDA said in a letter of enforcement discretion that it won't object to certain qualified health claims related to yogurt consumption and reduced risk of type 2 diabetes provided that the qualified health claims are worded in a way that doesn't mislead consumers, among other considerations.
A qualified health claim is supported by scientific evidence but doesn't meet the more rigorous "significant scientific agreement" standard required for an authorized health claim, the regulator said.
The FDA responded to a qualified health claim petition submitted on behalf of Danone North America. After reviewing the petition and other evidence related to the claim, it determined that there is some credible evidence supporting a relationship between yogurt intake and reduced risk of type 2 diabetes but that the evidence is limited.
"We know that a growing body of research suggests regular yogurt consumption could reduce your risk of developing one of the most significant and rapidly rising health ailments in the United States. That's why we decided to submit a petition for this first-of-its-kind qualified health claim," said Miguel Freitas, vice president of health and scientific affairs at Danone North America.
Write to Denny Jacob at denny.jacob@wsj.com
(END) Dow Jones Newswires
March 01, 2024 15:57 ET (20:57 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations